However, the use of isoform-selective inhibitors that can selectively target specific pathways, such as NLRP3 in CAPS, could avoid the drawbacks and toxicity associated with current HSP90 inhibitors, offering an exciting option in CAPS treatment. Here, HSP90AA1 is linked to cryopyrin-associated periodic syndrome.